First AD

Second AD

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Lower-Risk MDS: Current and Future Treatment Strategies

Moffitt Cancer Center

Cancer Centers

Partner

Comprehensive insights on the differences and similarities in treatment algorithms for physicians treating patients with MDS in and outside the United States. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.

Lower-Risk MDS: How Do Practice Patterns Compare Worldwide?

Myelodysplastic Syndrome: Overview of Diagnosis, Classification, and Treatment

Clinical Insights into the COMMANDS Trial

MEDALIST Trial: Luspatercept in Patients with Lower-Risk MDS

Recent Updates for Second-Line Treatment Options in Lower-Risk MDS

Clinical Implications of Recent Data on New Agents in Lower-Risk MDS

Real-World Data for Luspatercept in Lower-Risk MDS

Treatment Strategies and Sequencing in MDS

Unmet Needs and Future of Lower-Risk MDS